2011China Modern MedicineRequires access

The clinical effect of mesalazine combined with ligustrazine in treating ulcerative colitis

Zhou Maojing

Open publisher page 0 citations

Abstract

0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.

About this research paper

What this paper is about

0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.

Key concepts: Mesalazine, Medicine, Ulcerative colitis, Gastroenterology, Internal medicine, Colitis, Clinical efficacy, Disease

Related papers

Back to paper searchBrowse research topicsOriginal source
The clinical effect of mesalazine combined with ligustrazine in treating ulcerative colitis — Research Paper | ScholarLens